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Inactivating germline mutations within the adenomatosis poly-
posis coli (APC) gene underlie familial adenomatous polyposis
(FAP), a dominantly inherited syndrome characterized by the
development of hundreds to thousands of polyps in the colon and
rectum beginning in the teen years, with the majority of patients
developing colon cancer at about age 40. Additionally, variable
extracolonic manifestations can also be detected in mutation
carriers: gastric and duodenal polyps, osteomas, retinal lesions,
and desmoid tumours (Groden et al, 1991; Leppert et al, 1990;
Burt and Samowits 1988; Nishisho et al, 1991). Most inherited
mutant alleles of the APC gene that are associated with the clas-
sical form of the FAP lead to truncation of the protein product, are
scattered throughout the gene, and seem to be family specific (van
der Luijt et al, 1997; Giarola et al, 1999; Wallis et al, 1999; Ficari
et al, 2000). Several mutations are recurring in various ethnic
groups, with some mutations attributed to a founder effect (Spirio
et al, 1999) and other mutations, to a mutational hot spot (Beroud
and Soussi, 1996). Notably, a 5 base pair deletion mutation
(c.3927-c.3931 delAAAGA) known as codon 1309 termination
mutation is the most common germline mutation detected (APC
mutation database) and results in a severe form of FAP (Spirio 
et al, 1999; Wallis et al, 1999; Ficari et al, 2000). 
A subset of FAP families have a less aggressive form of the
disease, termed attenuated APC (AAPC), where the number of
polyps in the colon is usually less than 100, with a later age at
diagnosis of both polyposis and cancer than classical FAP (Spirio
et al, 1993; Samowitz et al, 1995). In fact, some individuals who
bear the AAPC alleles have as few as one polyp (Soravia et al,
1998). The regions within the APC gene that are associated with
an attenuated phenotype include the 5´ end of the gene (coded by
exons 1–5) (Spirio et al, 1993; Samowitz et al, 1995; Soravia et al,
1998), exon 9 (van der Luijt et al, 1995; Soravia et al, 1998; Young
et al, 1998; Rozen et al, 1999), and the 3´ end of the large exon 15
(Scott et al, 1995; van der Luijt et al, 1996; Brensinger et al, 1998;
Soravia et al, 1998; Matsubara et al, 2000). Surprisingly, even a
cytogenetically visible interstitial 5q deletion that deletes the
entire APC gene, intuitively predicted to result in a classical FAP
phenotype, has been reported to result in an AAPC phenotype
(Pilarski et al, 1999). 
A novel missense mutation within the APC gene, I1307K, has
been described initially in Jewish individuals of East European
descent (Ashkenazi), both at risk for colorectal cancer (CRC), and
also in the general, average risk, population of the same ethnic
extraction (Laken et al, 1997, Woodage et al, 1998). Studies
involving I1307K carriers have shown a moderate increase (up to 2
fold) in colon cancer risk (Laken et al, 1997; Rozen et al, 1999).
This specific polymorphism was considered to be limited to
Ashkenazi Jews (Laken et al, 1997; Prior et al, 1999), but it was
recently found in Jewish individuals of non-Ashkenazi origin as
well (Rozen et al, 1999; Patael et al, 1999). 
About 10–15% of all CRC are attributed to the familial form of
the disease, hallmarked by an earlier age at diagnosis (< 50 years)
than the general population. Hereditary non-polyposis colon
cancer (HNPCC) accounts for about 30–35% of familial cases, and
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accounts for only a minority of these familial cases. Yet, the
majority of familial and early onset cases remain genetically unac-
counted for. We hypothesized that APC germline mutations within
gene regions associated with an attenuated phenotype, might
contribute to ‘familial’ or early onset colorectal cancer. To test this
notion, we analysed the relevant regions of the APC gene for
germline mutations in a panel of Israeli patients with CRC who
had either familial or early onset cancer, who were treated in a
single medical centre in Israel. 
MATERIALS AND METHODS 
Patients 
All analysed patients had clinical and pathological confirmation of
CRC, and were being treated and followed up at the Oncology
Institute at the Rabin Medical centre. The Institutional review
board approved the study, and each participant signed a written
informed consent. All clinical details were retrieved by a detailed
questionnaire filled by the patients, and extraction of data from the
medical records and pathology reports. Patients were designated as
familial CRC if they had at least one additional first or two addi-
tional second-degree family members with CRC, regardless of age
at diagnosis. Early ages at onset were patients in whom cancer was
diagnosed under the age of 50 years. Patients who fulfilled the
Amsterdam or Bethesda II criteria for HNPCC (OMIM # 114500)
(OMIM database) were excluded from analysis. The control popu-
lation included DNA stored at the Chaim Sheba Medical Center
Genetics Institute, from women who were screened for carrier
status of some of the common recessive diseases (e.g. Cystic
fibrosis, Gaucher, Canavan). 
DNA extraction 
Genomic DNA was prepared from anticoagulated venous blood
samples using standard techniques, employing the Gentra Kit
(Gentra Inc., Minneapolis, MN) and using the manufacturer’s
recommended protocol. 
PCR and DGGE analysis APC exons 1–5 and 9 
Analysis of exons 1–5 and exon 9 of the APC gene was carried out
using flanking intronic primers, and implementing the PCR proto-
cols that were previously described (Olschwang et al, 1993). The
resulting PCR products were subjected to denaturing gradient gel
electrophoresis (DGGE) under the conditions described previously
(Olschwang et al, 1993). All consistently abnormally migrating
fragments (i.e. repeated abnormalities on three independent PCRs)
were subject to sequence analysis using the Big Dye terminator kit
(PE Biosystems, Foster City, CA), and using the ABI Prism 310
semiautomatic DNA sequencer (PE Biosystems). 
PCR and Protein Truncation Test (PTT) analysis of exon
15 of the APC gene 
PTT analysis was used by adopting the protocol previously
described (van der Luijt et al, 1997) and using the transcription
translation kit by Promega (Madison, WI). The translated PCR
products were analysed on polyacrylamide gels, vacuum-dried,
and exposed to X-ray film for 24–48 h. 
Detection of the I1307K, 1309del5 and E1317Q variants
by DGGE 
Detection of these mutations included PCR amplification of the
relevant genomic region contained in exon 15 (spanning
nucleotide c.3900 to c.4034, codons 1294 to 1338) followed by
DGGE analysis, using the protocol previously published by us
(Patael et al, 1999). For analysis of the 11307K mutation, we also
used a modified restriction analysis as detailed elsewhere
(Shtoyerman-Chen et al, 2000). Briefly, the following primers
were used to amplify the relevant region within exon 15 of the
APC gene: forward primer (sense) 5′ -GCA GAT TCT GCT AAT
ACC CTG CAA ATA GCA TTAA-3′ ; reverse primer (antisense)
5′ -CCT GAA GAA AAT TCA ACA GCT TTG TGC CTG-3′ .
PCR were performed using standard 10X PCR buffer, in a 50 µ l
reaction volume, using the M. J. Research PTC 100–60 thermocy-
cler (M. J. Research Inc., Watertown, MA). Thirty cycles of ampli-
fication with the annealing temperature set at 55˚C for 1 min were
employed. Following thermal cycling, 25–50% of the PCR prod-
ucts were digested with MvaI enzyme (New England Biolabs), for
3h  a t  3 7 ˚C, and resolved on a 2.5% agarose gel with UV
Transillumination. The mutant allele deletes the MvaI site.
Abnormally migrating bands on DGGE that did not harbor the
I1307K mutation were subjected to direct DNA sequencing, as
detailed above. 
RESULTS 
Patients’ and tumour characteristics 
Overall, 85 patients were analysed: 48 men and 37 women. There
were 50 patients of Ashkenazi origin, 22 non-Ashkenazis, 10 of
mixed origin and 3 Israeli Arabs. The age at onset was 50± 13.8
years (median ± SD) range 24–84 years. A total of 50 patients
(58.8%) had first-degree relatives with cancer: 37 (74%) had rela-
tives with colorectal cancer, 5 (10%) with other gastrointestinal
malignancies, 3 (6%) had relatives with breast/ovarian cancer and
in 10 patients – other malignancies were noted in relatives. The
majority of the patients (45/85–52.9%) had Dukes stage B, and 23
(27%) had Dukes stage C. Tumours were most commonly located
at the rectosignmoid region (n = 50–58.8%), in 18 (21.2%) the
tumour was located in the right colon, 8 patients (9.4%) had CRC
in the descending colon, and 8 others in the transverse colon. One
patient had two distinct tumours: one in the caecum and the other
in the rectosigmoid. Twenty-one patients (24.7%) had previous or
(n = 19) concurrent (n = 2) colonic polyps, with six having more
than one polyp. 
Mutation analyses of the relevant APC gene regions 
No abnormal patterns suggestive of truncating mutations in PTT
analysis of exon 15 were detected in any of the patients with any of
the fragments (data not shown). DGGE analysis of exons 1– 4 and
exon 9 did not display any abnormal migrating fragments sugges-
tive of harboring sequence alterations. A common migration
abnormality in the fragment containing exon 5 was detected: 14
samples showed a heterozygous pattern and two a mutant homozy-
gous pattern. Sequence analysis revealed a T to a G change 
32 bases from the splice junction of exon 5, in intron 5 (IVS5+32
T - > G) in all sequenced samples. 
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Consistent migration abnormalities were detected in 12 patients in
the mutation cluster region of exon 15. Of these, 8 (9.4% of all
patients and 16% of the Ashkenazis) were I1307K mutation
carriers, and the rest (n = 4) were E1317Q missense mutation
carriers. Of the 21 patients with colonic polyps, two (9.5%) were
I1307K mutation carriers and one (4.75%) carried the E1317Q
missense mutation. No mutations in codon 1309 were detected
(APC mutation database). Among the control population the
I1307K mutation was detected in 8/148 (5.4%) Ashkenazi women,
and the E1317Q mutation in two (2.7%) women. Naturally these
tests were performed anonymously, no details as to the personal or
family history of colonic polyps or cancer is available from these
individuals. 
DISCUSSION 
The rationale that led to analysis of the specific APC gene regions
in the present study’s patients is based on several observations.
First, few if any mutations in any known CRC predisposition genes
have been reported in the majority of early onset or non-syndromic
‘familial’ CRC patients. Second, the relatively mild phenotype that
is associated with germline mutations within the APC gene in the
regions analysed. The finding of significantly more FAP-associ-
ated extracolonic manifestations in seemingly sporadic CRC
patients compared with controls (Dunlop et al, 1996), may also
implicate germline mutations within the APC gene in the patho-
genesis of non FAP CRC. Yet, in our group of patients, no trun-
cating, disease-causing mutations were detected in the APC gene
within the regions that are associated with attenuated APC pheno-
type. 
One reason for not detecting mutations could be the lack of
sensitivity of the mutation detection schemes used: DGGE and
PTT. This seems unlikely, though, as both techniques have been
applied to this specific gene, and have been shown to detect muta-
tions within the analysed regions (van der Luijt et al, 1997).
Moreover, in this study, a novel polymorphism and two known
missense mutations were detected using DGGE. Alternatively,
mutations in other regions of the gene that were not analysed in the
present study (e.g., other exons, intronic or promotor sequences),
or even major gene rearrangements not detected by PCR-based
analyses could exist. 
Another possible reason for not detecting existing mutations is
patient selection criteria. Indeed, if more individuals with multiple
colonic adenomas would be analysed, perhaps truncating muta-
tions could be found, as these features are more prevalent in atten-
uated APC phenotype (Spirio et al, 1993; Samowitz et al, 1995).
However, the criteria used for patient inclusion are well estab-
lished and accepted. Moreover, confirmation as to the appropriate
selection of patients is also provided by the rate of I1307K muta-
tion carriers among the tested Ashkenazi individuals, a rate that is
similar to that reported for familial CRC Jewish patients (Laken 
et al, 1997; Rozen et al, 1999). 
Previous analysis of the APC gene in non-APC families has
been previously reported in a few studies. Wallis and co-workers
identified three missense mutations among 15 non-APC colorectal
cancer in England (Wallis et al, 1999). In contrast, no mutations
within the first 6 coding exons were detected among 40 familial or
early onset British patients with CRC (Joyce et al, 1995). More
recently, analysis of 79 patients with early onset and/or familial
CRC whose tumors show no microsatellite instability, failed to
detect truncating mutations in any of the APC exons (Boardman 
et al, 2001). 
There were 12 individuals in this study who displayed one of
two missense mutations within the APC gene: I1307K and
E1317Q. The role of the I1307K mutation in predisposing to colon
cancer is well established (Woodage et al, 1998; Rozen et al, 1999;
Gryfe et al, 1999). Less certainty still exists as to the role of the
E1317Q mutation in CRC predisposition. Frayling and co-workers
(1998) initially detected this missense mutation in 4/164 (2.4%)
patients with colon cancer in none of the controls, implicating an
association of the E1317Q mutation in CRC pathogenesis.
Moreover, this missense mutation was significantly more prevalent
in individuals with multiple adenomas than in controls (Lamlum et
al, 2000). However, analysis of a larger number of individuals
revealed the mutation at a similar rate (about 0.5–0.6%) in both
patients and controls (Popat et al, 2000). The data in the present
study seem to be consistent with the notion that this variant repre-
sents a polymorphism, as it was detected in both patients and
controls. However, a larger study encompassing more individuals,
affected and controls, is certainly needed to assess the role, if any,
that this mutation plays in CRC predisposition. 
In conclusion, no inactivating, disease-causing mutations in the
APC gene regions that are associated with an attenuated phenotype
have been detected in Israeli patients with either familial or early
onset colon cancer. The precise genes that do underlie this
apparent inherited predisposition in these individuals remain
elusive. 
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